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Introduction: The tyrosine kinase Met receptor regulates a complex
array of cellular behaviors known collectively as invasive growth.
Although essential for normal development and wound repair, this
pathway is frequently deregulated in tumors to promote their
growth, motility, and invasion. Accordingly, Met is overexpressed
in a variety of human tumors, and this aberrant expression correlates
with a poor patient prognosis. Previous studies have shown that Met
receptor levels are governed in part by Cbl-mediated ubiquitination
and degradation, and the uncoupling of Met from this pathway
promotes its transforming activity.
Methods: Here, we describe a novel mechanism of Met degradation
in Non Small Cell Lung Cancer Cells and HeLa cells using western
blot, immunocytochemistry, immunoprecipitation assay, invasion
assay, cell viability assay and in vivo tumor growth model.
Results: Met receptor interacted with the C-terminus of heat shock
protein 70-interacting protein (CHIP), leading to proteasomal deg-
radation of the receptor in vitro. In addition, CHIP overexpression
destabilized endogenous Met receptor in lung cancer cells, whereas
CHIP knockdown increased Met receptor expression, indicating an
essential role for CHIP in the regulation of Met degradation. CHIP
overexpression inhibited Met-mediated lung cancer cell growth and
invasion. Finally, we confirmed these results by tumor xenograft
model.
Conclusion: Based on these findings, we conclude that CHIP is a
suppressor of Met function, serving to regulate cellular receptor
levels by promoting Met receptor degradation.
Key Words: C-terminus of Hsp70-Interacting Protein (CHIP), Met,
Proteasomal degradation, Ubiquitination.
(J Thorac Oncol. 2011;6: 679–687)
Met is a membrane receptor for hepatocyte growth factor(HGF) 1/scatter factor with tyrosine kinase activity. On
stimulation, Met receptor elicits a variety of cellular re-
sponses that are thought to be involved in invasive growth.1
Met receptor is expressed according to the cellular context
and developmental stage of the organism.2,3 Aberrant Met sig-
naling likely contributes to tumor progression and metastasis;
elevated Met expression has been detected in many late-stage
tumors and is often an indicator of a poor prognosis.4–6
Following ligand stimulation, several receptors, includ-
ing epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor, are internalized, ubiquiti-
nated, and degraded by the lysosomal pathway to control
receptor signaling.7 Although the mechanisms underlying
EGFR endocytosis and trafficking have been extensively
studied,8 interest in Met receptor and its trafficking, mecha-
nism of degradation, dephosphorylation, and protein-protein
interactions is increasing. The predominant mechanism of
Met down-regulation involves its rapid internalization from
the plasma membrane and subsequent lysosomal degradation;
however, a role for the proteasome in Met degradation has also
been suggested.9 Recent data indicate that the proteasomal
degradation of Met occurs after acute HGFs-induced Met endo-
cytosis through binding to ubiquitin (Ub) ligases.10 Similar
results have been described for growth hormone receptor.11
C-terminus of heat shock protein 70-interacting protein
(CHIP) is a well-described U-box-type E3 Ub ligase that
induces the ubiquitination and proteasomal degradation of its
substrates, including glucocorticoid receptor, c-Raf kinase,
ErbB2, and other oncogenic proteins.12–14 In this study, we
identified CHIP as a physiologically negative regulator of
Met receptor that functions through a novel mechanism
involving CHIP-mediated ubiquitination and proteasomal
degradation. This study is the first to describe the relationship
between CHIP and tumor progression by the proteasomal
degradation of Met in lung cancer cells.
MATERIALS AND METHODS
Materials
The following antibodies and reagents were used in this
study: anti-CHIP (SC-33264), anti-hemagglutinin (HA; sc-
7392), anti-Hsp70 (sc-1060), and anti-Hsp90 antibodies (sc-
1055) (Santa Cruz Biotechnology, Santa Cruz, CA); protein
A/G plus agarose beads (sc-2003) (Santa Cruz Biotechnol-
ogy); MG132 (c2211) (Sigma, Indianapolis, IN); anti-His6
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(2365); and anti-Ub antibodies (3936) (Cell Signaling, Bos-
ton, MA); 10X lysis buffer (9803) (Cell Signaling); horse-
radish peroxidase-conjugated secondary antibodies and Su-
perSignal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL); anti-Met antibodies (ab51067) (Abcam, Cam-
bridge, UK); Bradford Protein Assay Kit (Bio-Rad Labora-
tories, Hercules, CA); fetal bovine serum (FBS; HyClone
Laboratories, Logan, UT); and Lipofectamine Plus Reagent
(Invitrogen, Carlsbad, CA).
Cell Lines and Transient Transfection
HeLa human cervical carcinoma and H358 lung cancer
cells were purchased from the American Type Culture Col-
lection (Manassas, VA). HeLa cells were maintained in
minimum essential medium (HyClone Laboratories) supple-
mented with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate,
0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate,
50 U/ml penicillin, 50 g/ml streptomycin, and 10% FBS.
H358 cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 (HyClone Laboratories) supplemented with
10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, and
2 mM glutamine in a humidified atmosphere of 5% CO2 and
95% air at 37°C. For transfection, cells were seeded to 80%
confluence and transfected using Lipofectamine Plus Reagent
(Invitrogen) according to the manufacturer’s guidelines.
Where indicated, the transfected cells were treated with
MG132 or an equivalent amount of vehicle (dimethyl sulfox-
ide) for the indicated time periods.
Plasmid Construction and Small-Interfering
RNA Constructs
DNA fragments encoding full-length CHIP were am-
plified by polymerase chain reaction and subcloned into
pcDNA containing the sequence for His6 (Invitrogen). Sim-
ilarly, Met was cloned into pcDNA3 (Invitrogen). For the
knock down of CHIP expression, HeLa or H358 cells were
transfected with either a CHIP (sc-43555) or negative
control small-interfering RNA (siRNA) (sc-37007) (Santa
Cruz Biotechnology).
Cell Lysis, Immunoprecipitation, and
Immunoblotting
Cells were lysed in a buffer (Cell Signaling) containing
20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1
mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5
mM sodium pyrophosphate, 1 mM -glycerophosphate, 1
mM Na3VO4, 1 mg/ml leuptin, and 1 mM phenylmethylsul-
fonyl fluoride. Protein concentrations were determined using
a Bradford assay kit (Bio-Rad Laboratories). The lysates (50
g per lane) were resolved by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred to
polyvinylidene fluoride membranes, and probed with the
indicated antibodies. All primary antibodies were detected
with horseradish peroxidase-conjugated secondary antibodies
and visualized using enhanced SuperSignal West Pico
Chemiluminescent Substrate. The band density was quanti-
fied using a Bio-Rad Gel Documentation System. Immuno-
precipitation experiments were performed by the addition of
15 l of protein A/G agarose to cell lysates at 4°C for 1 hour
on a rotating platform. After several washes, the bound
proteins were subjected to SDS-PAGE and detected by im-
munoblotting.
Ubiquitination Assay
H358 and HeLa cells were transfected with HA-tagged
Ub (HA-Ub) or UbK0 and Met, with or without pcDNA-his6-
CHIP. Forty-eight hours later, the cells were lysed and
immunoprecipitated using anti-Met antibodies. The anti-Met
immunoprecipitates were resolved by SDS-PAGE and blotted
with anti-HA antibodies to detect ubiquitination.
Cell Viability Assays
To assess, we used the colorimetric MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) as-
say. Cell suspensions were seeded into 96-well microtiter
plates and transfected with His6-CHIP, at various concentra-
tions. After incubation for 48 hours at 37°C, 20ul of MTT
solution was added to each well and incubation then contin-
ued for a further 4 hours at 37°C.
Invasion Assays
The invasive potential of the H358 cells was tested
using Matrigel invasion chambers (24-well format, 8-m
pore size; BD Biosciences) as described previously. Briefly,
150,000 cells suspended in RPMI 1640 containing 1% FBS
were transferred to an insert chamber. In the lower chamber,
RPMI 1640 containing 10% FBS served as the source of the
chemoattractants. After 24 hours, the cells on the upper
surface of the filter were wiped away with a cotton swab. The
cells on the lower surface of the filters were fixed with
methanol for 10 minutes, stained with Giemsa for 3 hours,
and counted. For each replicate, cells in three randomly
selected fields were counted. The invading cells were quan-
tified by dissolving the stained cells in 10% acetic acid
(100–200 l/well) and transferring a consistent amount of the
dye/solute mixture to a 96-well plate for colorimetric OD
readings at 560 nm.
Immunocytochemistry
Cells were plated in four-well slide chambers (Sonic
Seal Slide, Nalgene Nunc, Rochester, NY) and grown in
serum-free RPMI 1640 for 24 hours. H358 cells were fixed
with 4% paraformaldehyde, washed in phosphate-buffered
saline containing 0.2% NP-40, and blocked with 10% goat
serum in phosphate-buffered saline. The cells were then
probed overnight with anti-Met, anti-His6, and anti-CHIP
primary antibodies and stained with the appropriate fluores-
cence-conjugated secondary antibodies for 1 hour. Images of
the stained cells were obtained by immunofluorescence mi-
croscopy (Olympus, Melville, NY).
In Vivo Xenograft Model
BALB/cAJcl-nu/nu female mice at 5 weeks of age were
purchased from Charles River Laboratories (Wilmington,
MA). H358 cells were cultured as monolayers, trypsinized,
and resuspended in an equal volume of Matrigel (BD Bio-
science) at 1.0  108 cells per ml, respectively. Female nude
mice were given bilateral subcutaneous injections of 1.0 
107 (0.1 mL) H358 cells which stably expressed green fluo-
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rescent protein (GFP) and GFP-CHIP. The mice were kept in
a pathogen-free environment. Tumor growth was monitored
twice each week by measuring the tumor size using calipers;
tumor volume was determined using the formula V  1/2 
larger diameter  (smaller diameter)2. The mice were killed
and the tumor tissues were collected, lysed, and immunoblot-
ted. All animal experiments were carried out under an Insti-
tutional Animal Care and Use Committee-approved protocol,
and institutional guidelines for the proper and humane use of
animals were followed.
RESULTS
CHIP Expression Regulates Met Protein Levels
To investigate the effects of CHIP overexpression on
steady-state levels of Met, HeLa cells were cotransfected
with constructs expressing CHIP (pcDNA-His6-CHIP),
pcDNA-His6 empty vector and Met (pcDNA3-Met), and the
Met protein levels subsequently determined by immunoblot
analysis. As shown in Figure 1A, CHIP overexpression de-
creased the level of Met. We next examined whether the
down-regulation of Met by CHIP could be inhibited by a
CHIP-specific siRNA and scramble siRNA. As shown in
Figure 1B, compared with cells transfected with CHIP alone,
cotransfection with the CHIP siRNA expression construct
(CHIPi) decreased the levels of exogenous CHIP. In addition,
cotransfection of the CHIP siRNA attenuated the down-
regulation of Met induced by exogenous CHIP (Figure 1B).
Collectively, these results demonstrate that CHIP overexpres-
sion specifically down-regulates Met protein expression in
HeLa cells.
To examine the role of endogenous CHIP in the regu-
lation of Met expression, HeLa cells, which are known to
express CHIP,15 were cotransfected with or without CHIPi
and pcDNA3-Met and the levels of Met assessed. Figure 1C
demonstrates that the expression of CHIP siRNA decreased
the levels of endogenous CHIP, resulting in increased Met
expression. These data indicate that endogenous CHIP plays
a role in the regulation of Met levels in HeLa cells.
CHIP Downregulates Met Through the
Ub-Proteasome Pathway
To determine whether proteasome activity is required
for the down-regulation of Met by CHIP, HeLa cells cotrans-
fected with pcDNA-His6-CHIP, pcDNA-His6, and pcDNA3-
Met were treated with the protease inhibitor MG132 and
subjected to immunoblotting. As shown in Figure 2A, treat-
ment with MG132 for 6 hours completely blocked the CHIP-
induced down-regulation of Met. To examine whether polyu-
biquitination is required for CHIP-induced Met degradation,
we used a mutant form of Ub, UbKO, in which the lysines are
mutated to arginine.16 Expression of UbKO, but not wild-type
Ub, restored Met protein levels (Figure 2B), demonstrating
that CHIP stimulates Met degradation through Ub-dependent
proteasomal degradation.
We next assessed the contribution of the Ub ligase
activity of CHIP to Met degradation. Cell lysates prepared
from transfected HeLa cells were immunoprecipitated with
anti-Met antibodies and immunoblotted with anti-His6 to
assess the interaction of CHIP and Met. As shown in Figure
2C, CHIP interacted with Met and decreased Met expression.
These results indicate that the interaction of CHIP with Met
and CHIP Ub ligase activity are required for CHIP-targeted
Met degradation.
CHIP Interacts with Endogenous Met in Lung
Cancer Cells, Inducing Receptor Ubiquitination
and Degradation
Having demonstrated a role for CHIP and its associated
chaperones in the degradation of exogenous Met in HeLa
FIGURE 1. C-terminus of Hsp70-interacting protein (CHIP)
expression regulates Met protein levels. A, CHIP overexpres-
sion down-regulates Met protein levels. HeLa cells were
transfected with pcDNA3-c-Met, pcDNA-his6, and incremen-
tal concentrations (0–2 g) of pcDNA-his6-CHIP. B, CHIP-
small-interfering RNA (siRNA) expression attenuates CHIP-
induced Met down-regulation. Upper, HeLa cells were
cotransfected with pcDNA-his6-CHIP with or without CHIPi
as indicated (, scramble siRNA; , CHIP siRNA). Lower,
HeLa cells were transfected with pcDNA3-Met, pcDNA-his6-
CHIP, and CHIPi. C, The knockdown of endogenous CHIP
increases Met levels. HeLa cells were transfected with
pcDNA3-Met and CHIPi as indicated. In all experiments, 3 
105 HeLa cells were plated in 60-mm dishes, cultured in
minimum essential medium with 10% fetal bovine serum,
and transfected with Lipofectamine Plus Reagent. Cell lysates
were prepared 48 hours after transfection. Protein levels
were determined by immunoblotting with the indicated an-
tibodies. Exogenous His6-CHIP and endogenous CHIP were
detected using anti-His6 and anti-CHIP antibodies, respec-
tively. -actin was used as a transfection control. Representa-
tive results from two independent experiments, each per-
formed in duplicate, are shown.
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cells, we next sought to examine the effects of CHIP stability
and function on endogenous Met expression in lung cancer
cells. We first examined the expression pattern of Met and
CHIP in lung cancer cell lines. The cell lines showed the
endogenous reciprocal expression of CHIP and Met protein
inversely (Figure 3A). Next, as shown in Figure 3B, Met was
expressed in H358 cells, which was bronchoalveolar carci-
noma with wild type EGFR; however, CHIP expression was
weak in these cells. The colocalization of CHIP and Met was
observed, which is consistent with the Met-CHIP interaction
detected in our cotransfection experiments. We also con-
firmed the expression of CHIP and Met in H358 cells through
immunoblot analysis (Figure 3A).
It has been proposed that CHIP functions as a general
Ub ligase, mediating the ubiquitination of unfolded or mis-
folded proteins in a chaperone-dependent process. To inves-
tigate the effects of CHIP overexpression on the steady-state
levels of Met, H358 cells were transfected with CHIP and the
level of Met assessed. Figure 3C demonstrates that, after the
incremental transfection of CHIP, Met expression was re-
duced in a dose-dependent manner. Thus, CHIP overexpres-
sion mediates Met degradation in H358 cells. We next as-
sessed the ability of CHIP and Met to associate in H358 cells
through immunoprecipitation analysis using H358 cells trans-
fected with exogenous CHIP. As shown in Figure 3D (upper
panel) CHIP and Met immunocomplexes were precipitated
by Met-specific or anti-His6 antibodies, suggesting that CHIP
associates with endogenous Met in H358 cells. In addition, as
shown in Figure 3D (upper panel), Hsp70 but not Hsp90 was
detected in the precipitated Met complex indicating that
CHIP down-regulates Met levels in lung cancer cells through
its association with endogenous Met-Hsp70 complexes. Ad-
ditionally, we detected for Hsp70, Hsp90, Met and CHIP
expression using specific antibodies in whole cell lysate, and
then find out that is not difference both of Hsp70 and Hsp90
expression between His6 empty vector and His6-CHIP over-
expression (Figure 3D, lower panel).
To determine whether CHIP promotes the polyubiquiti-
nation of endogenous Met, we examined the ubiquitination
status of Met in H358 cells transfected with HA-Ub in the
presence and absence of exogenous CHIP. To inhibit the
proteasomal degradation of polyubiquitinated proteins, trans-
fected cells were treated with MG132 for 6 hours before
harvesting. As shown in Figure 3E, we were able to coim-
munoprecipitate HA-Ub with Met, suggesting that the protein
is ubquitinated. To assess the total level of protein ubiquiti-
nation, whole-cell lysates were immunoblotted using anti-HA
antibodies. The polyubiquitinated Met exhibited a typical
high-molecular-weight smear, the intensity of which was
increased in the presence of exogenous CHIP, suggesting
that CHIP expression elevates Met receptor polyubiquiti-
nation (Figure 3E, upper panel). In contrast, CHIP did not
affect total cellular protein ubiquitination, suggesting a
Met-specific effect (Figure 3E, lower panel). Taken to-
gether, these results suggest that CHIP, by facilitating
receptor ubiquitination, specifically targets endogenous
Met for proteasomal degradation.
The Knockdown of Endogenous CHIP Increases
Met Receptor Expression in H358 Cells
To assess the effects of endogenous CHIP on Met
receptor levels, we performed CHIP knockout experiments
using scramble siRNA or CHIP siRNA. The transfection of
H358 cells with CHIPi decreased the levels of endogenous
CHIP (Figure 4A, upper panel) and increased the level of Met
receptor (Figure 4A, lower panel), indicating that endogenous
CHIP regulates the basal turnover of Met in lung cancer cells.
As described in Figure 3D, CHIP interacted with Met by
Hsp70 mediated binding, but not Hsp90. Further experiments
were then performed to assess the interaction between endog-
enous CHIP and Met by immunoprecipitation with anti-CHIP
or Met antibodies and immunoblotting with anti-CHIP, Met,
FIGURE 2. The proteasome inhibitor MG132 and ubiquitin
(Ub) mutant UbKO can inhibit C-terminus of Hsp70-interact-
ing protein (CHIP)-induced Met degradation. A, The protea-
some inhibitor MG132 inhibits CHIP-induced Met down-
regulation. HeLa cells were transfected with pcDNA3-Met
along with empty pcDNA-His6 (, vector control) or
pcDNA-His6-CHIP (), followed by treatment with dimethyl
sulfoxide (vehicle) or 10 M MG312 for 6 hours before im-
munoblot analysis. The protein levels of Met and CHIP were
determined by immunoblotting with anti-Met, anti-His6,
and anti-CHIP antibodies, respectively. B, Expression of the
Ub mutant UbKO blocks CHIP-induced Met down-regulation.
HeLa cells were transfected with pcDNA3-Met with pcDNA-
His6 (, vector control) or pcDNA-His6-CHIP (), pcDNA-Ub,
or pCS2-UbK0, as indicated. Met protein levels were deter-
mined by immunoblotting with anti-Met antibodies. C, The cell
lysate were immunoprecipitated using a poly anti-Met anti-
body. The immunoprecipitants were immunobltotted with an-
ti-His6 antibody (upper panel). The corresponding cell lysates
were probed using anti-His6, anti-Met and anti- actin. Relative
Met levels are presented as the mean  SE of three indepen-
dent experiments, each performed in duplicate.
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Hsp70 or Hsp90 antibodies, respectively. The results showed
that CHIPi induces the dissociation of Met and CHIP by
decreased interaction Hsp70, but not Hsp90 (Figure 4B, left
and right panel). To explore the role of CHIP in Met receptor
degradation further, we examined the Met ubiquitination
status of CHIPi-transfected cells. Figure 4C demonstrates that
reduced CHIP expression markedly decreased the intensity of
the ubiquitinated Met smear, suggesting a reduction in Met
receptor polyubiquitination in the absence of CHIP.
CHIP Overexpression Inhibits the Met-Induced
Growth and Invasion of H358 Cells
Having established a role for CHIP in the ubiquitination
and turnover of Met, we next examined the effects of CHIP
on H358 cell growth and invasion. H358 cells were tran-
siently transfected with pcDNA-His6-CHIP or control
pcDNA-His and examined 48 hours later for cell growth via
an (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay. CHIP overexpression was found to inhibit the
proliferation of H358 cells (Figure 5A), consistent with a loss of
Met receptor function. As CHIP overexpression inhibited H358
cell growth, we sought to investigate the effects of CHIP
overexpression on H358 cell invasion. As shown in Figure 5B,
as the concentration of CHIP was increased (0.5–2 g DNA),
H358 cell invasion was significantly inhibited (Figure 5B).
These results demonstrate that CHIP regulates the motility of
H358 cells consistent with the inhibition of Met receptor activity
due to degradation.
FIGURE 3. C-terminus of Hsp70-interacting protein (CHIP) interacts with endogenous Met and induces Met ubiquitination
and degradation in H358 cells. A, Reciprocal expression of Met and CHIP proteins in non-small cell lung cancer. The expres-
sion pattern of Met (top) and CHIP (middle) was examined using standard immunoblotting of the whole cell lysates from the
following lung cancer cell lines cultured under serum-containing conditions (10% fetal bovine serum): A549, H358, H827,
H1975, and PC9. -actin was included as loading control (bottom). B, H358 cells express both Met and CHIP. Met and CHIP
fluorescence following immunoflourescent staining was imaged using an inverted microscope (Axiovert 40 CFL). C, CHIP over-
expression down-regulates endogenous Met levels in H358 cells. Forty-eight hours after transfection with His6-CHIP, whole-
cell lysates were prepared, and the levels of Met and CHIP were determined by immunoblotting with anti-Met and -His6 anti-
bodies, respectively. D, CHIP associates with the Met-Hsp complex in H358 cells. Cells transfected with exogenous CHIP were
immunoprecipitated with anti-Met antibodies. The presence of CHIP, Hsp70, Hsp90, or Met in the precipitated complexes
was determined by immunoblotting with anti-His6, anti-Hsp70, anti-Hsp90, or anti-Met antibodies, respectively. E, CHIP over-
expression enhances the polyubiquitination of endogenous Met in H358 cells. Whole-cell lysates were prepared and Met pre-
cipitated with anti-Met antibodies 48 hours after CHIP transfection. The presence of Ub-conjugated Met in the immunocom-
plex was detected using anti-hemagglutinin (HA) antibodies (upper). The same membrane was reprobed with anti-Met
antibodies to assess the level of precipitated Met (middle). Whole-cell lysates were resolved by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and probed with anti-HA antibodies to determine the level of total ubiquitinated proteins
(lower). In each case, representative results from two independent experiments, each performed in duplicate, are shown.
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CHIP Inhibits the Tumor Growth by
Down-Regulation Met In Vivo
We then examined whether tumor progression was
reduced when the expression level of CHIP was up-regulated.
We generated H358 cells that overexpressed GFP-CHIP and
GFP vector (GFP-CHIP and GFP; Figure 6A). To investigate
the effects of CHIP overexpression in vivo, six nude mice
received bilateral subcutaneous flank injections of GFP-CHIP
H358 cells or GFP control cells. Tumors were significantly
larger in mice injected with GFP H358 cells; however, little
tumor growth was observed in the mice injected with GFP-
CHIP cells (Figure 6A). To further determine whether CHIP
declines Met expression and inhibits phosphorylation of
Akt1/2 and ERK1/2, we colleted, lysed, and detected the
protein expression by immunoblotting with specific antibod-
ies in mouse tumor tissue. As shown in Figure 6B, C, Met
receptor was substantially down-regulated (Figure 6B) in the
mice injected with GFP-CHIP expressed cells than GFP cells
which also correlated with a concomitant inhibition of p-Met
and its downstream signaling molecules p-Akt1/2 and
p-ERK1/2 kinase. These results suggest that CHIP suppresses
tumor progression by inhibition of Met expression and down-
regulation both of Akt1/2 and ERK1/2 which is related with
Met downstream signal transduction.
DISCUSSION
The cellular level of Met receptor determines both
metastatic tendency and a poor prognosis.4–6 Steady-state
levels of Met receptor are tightly regulated through the
balance of receptor synthesis and turnover, according to
changing cellular conditions.9 Although it has been shown
that Met receptor degradation is primarily mediated by the Ub
lysosomal pathway,17–19 the molecular mechanism(s) by
which cells regulate Met stability are largely unknown. Here,
we report that CHIP plays a key role in the basal turnover of
Met receptor. CHIP reduced Met receptor expression by
enhancing its degradation through the Ub-proteasome path-
way. Consistent with these findings, we found that reducing
CHIP expression through CHIP-targeted siRNA knockout
increased Met receptor levels.
FIGURE 4. Reducing C-terminus of Hsp70-interacting protein (CHIP) expression enhances Met receptor protein levels. A, The
knockdown of endogenous CHIP increases Met levels. H358 cells were plated as in Figure 3C and transfected with control
small-interfering RNA (siRNA) or CHIPi using Lipofectamine Plus Reagent. Forty-eight hours after transfection, whole-cell ly-
sates were prepared and the levels of CHIP and Met determined by immunoblotting with anti-CHIP and anti-Met antibodies,
respectively. B, CHIP siRNA dissociates with the Met-Hsp complex in H358 cells. Cells transfected with scramble siRNA () and
CHIP siRNA () were immunoprecipitated with anti-Met or anti-CHIP antibodies. The presence of CHIP, Hsp70, Hsp90, or
Met in the precipitated complexes was determined by immunoblotting with anti-His6, anti-Hsp70, anti-Hsp90, or anti-Met
antibodies, respectively. C, Met ubiquitination is decreased in CHIP-knockdown cells. Experiments were performed as de-
scribed in A, and cell lysates were precipitated with anti-Met antibodies. The presence of Ub-conjugated Met in the immuno-
complex was detected by immunoblotting with anti-hemagglutinin (HA) antibodies (upper). The same membrane was re-
probed with anti-Met antibodies to assess the level of precipitated Met (middle). Whole-cell lysates were separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and probed with anti-CHIP antibodies to determine the total level of ubi-
quitinated proteins (lower). In each case, representative results from two independent experiments, each performed in dupli-
cate, are shown.
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In lung adenocarcinoma, mutations in the tyrosine ki-
nase domain of EGFR are of great clinical interest, as many
of these tumors are responsive to tyrosine kinase inhibitors
(TKIs).21,22 Although the majority of EGFR-mutant non-
small cell lung cancers initially respond to TKIs, most of
these tumors ultimately become resistant to drug treatment.
Recently, Engelman et al.23 reported that Met protooncogene
amplification led to gefitinib resistance in lung cancers lack-
ing a secondary T790M mutation. Bean et al.25 also demon-
strated that Met was amplified in lung tumors with acquired
resistance, and accounted for approximately 20% of cases of
acquired TKI resistance. As EGFR signaling is required for
tumor survival and persistence, these findings demonstrate
that cancer cells expressing activated Met before the devel-
opment of resistance can signal through Met receptor if
EGFR signaling is inhibited.25
A variety of small-molecule TKIs targeting Met have
been developed that display direct effects on tumor cells.27
However, most of these inhibitors were not assessed in
clinical trials due to their poor pharmacokinetic characteris-
tics because the majority of TKIs are ATP-mimetics and
compete (reversibly or irreversibly) with ATP binding within
the catalytic kinase cleft.28 Unlike monoclonal antibodies,
these inhibitors cross the plasma membrane and interact with
the cytoplasmic domain of cell-surface receptors or directly
modulate the function of intracellular signaling molecules.27
The chief limitation of these molecules is that they inhibit
kinase-dependent Met activation only. Several new small-
molecule TKIs have entered clinical testing and are thought
to be less specific than monoclonal antibodies; however, with
the advantage of reduced specificity comes a risk of increased
toxicity.28 Several newly developed TKIs (so-called multitar-
geted agents) show a broad range of activity against various
receptor tyrosine kinases, including EGFR, vascular EGFR,
FIGURE 5. C-terminus of Hsp70-interacting protein (CHIP)
inhibits H358 cellular proliferation and invasion. A, CHIP in-
hibits lung cancer cell growth in vitro. After transfection with
His6-CHIP, cell growth was determined by MTT analysis. B,
Cells were allowed to pass through membranes with 8-m
pores covered with Matrigel and gelatin (mixture of proteins
from basal membranes) to a lower chamber without fetal
bovine serum. The invading cells were detected by colori-
metric optical density readings at 560 nm.
FIGURE 6. C-terminus of Hsp70-interacting pro-
tein (CHIP) suppresses tumor growth in a mouse
xenograft model. A, CHIP inhibits tumor growth
in vivo. Ten weeks after the injections, the mice
were killed, and tumor tissues were collected. Left,
Representative nude mice injected with GFP (left)
and GFP-CHIP (right). Right, the graph showing
the tumor volume of the six tumors after 10
weeks. Bars represent mean  SD (n  6). B, Met
expression is reduced by CHIP overexpression in
vivo. Protein levels of CHIP, Met, and -actin in
the tumor tissue from xenograft model were de-
termined by immunoblotting using anti-CHIP, an-
ti-Met, and anti--actin antibodies. C, pAkt1/2
and pERK1/2 is down-regulated in the mice with
injected GFP-CHIP overexpressed cells in vivo.
Protein levels of CHIP, Met, Akt1/2, pAkt1/2,
ERK1/2, pERK1/2, and -actin in the tumor tissue
from xenograft model were determined by immu-
noblotting using anti-CHIP, anti-Met, and anti--
actin antibodies.
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and nonreceptor tyrosine kinases (e.g., SRC kinases or down-
streammolecules, including XL880,MP470, and PF2341066).29
The requirement of the C-terminal docking site for the trans-
forming activity of wild-type or mutant Met and the known role
of intracellular effector proteins suggest that the combined tar-
geting of these downstream components could be effectively
disrupted in Met-driven oncogenesis. For example, attempts to
target the SH2 domain of GRB2 and STAT3 using synthetic
peptides have been reported.26,29 Other strategies for targeting
Met signaling have focused on either Met coinducers or novel
agents targeting RON receptor.30 Accordingly, a dual inhibitor
of both RON and Met has been designed and found to impair
tumor growth.31 Other research efforts have focused on the
development of inhibitors using high-throughput screening ap-
proaches, rational drug design, or both. High-throughput com-
pound screening is one way to identifyMet inhibitors that can be
modified through medicinal chemical techniques to produce
clinically applicable drugs. Such assays are currently being used
to identify small-molecule Met inhibitors through measurements
of cell scattering.32,33
Structure-based approaches have been used to design
nucleic acid-directed gene silencing molecules (e.g., anti-
sense oligodeoxynucleotides, RNA interference, and ri-
bozymes) that prevent Met translation. Preclinical studies
have shown the success of these compounds through the
specific inhibition of tumor cell growth.34–36 Nevertheless,
nucleic acid-directed therapies require further investigation to
allow the establishment of their antitumor activity, optimum
delivery methods, pharmacokinetics, and toxic effects.37
Both the physiological and pharmacological down-regu-
lation of Met has been linked to the induction of receptor
ubiquitination, which targets the modified receptor for lysosomal
and proteasomal degradation.17–19 Taher et al.19 demonstrated
that Cbl mediates the HGF-induced ubiquitination of Met and is
a negative regulator of HGF/Met signaling in B cells. Shattuck
et al.18 reported that Met receptor interacted with the transmem-
brane protein LRIG1 independent of HGF stimulation, and that
LRIG1 destabilized the receptor in a Cbl-independent manner.
Accordingly, LRIG1 overexpression destabilizes endogenous
Met receptor in breast cancer cells, and impairs those cells’
ability to respond to HGF. LRIG1 knockdown increases the Met
receptor half-life, indicating its role in Met degradation.18 Fur-
thermore, Met has been identified as an Hsp90 binding partner,
and Hsp90 inhibitors have been reported to destabilize Met.38–40
In addition, Hsp90 inhibitors block theMet-dependent activation
of urokinase-type plasminogen activator, and HGF/scatter fac-
tor-mediated cell scattering and in vitro invasion.41 Finally,
multiple Met-activated downstream signaling proteins, includ-
ing AKT,42 RAF,43 and STAT,44 depend to some extent on their
association with HSP90.
CHIP is a Ub ligase that directs chaperone substrates
for ubiquitination and proteasomal degradation. CHIP inter-
acts with Hsp/Hsc70 and Hsp90 through its N-terminal tet-
ratricopeptide repeat domain and catalyzes Ub conjugation
through its C-terminal U-box domain. Importantly, CHIP has
been shown to negatively regulate Hsp70 and Hsp90 function
and to convert Hsp90 complexes from a chaperone function
to one that promotes the ubiquitination and degradation of
interacting proteins 12–15. Previous data suggest that ErbB2 is
a target of CHIP Ub ligase activity. CHIP associates with
ErbB2 in vivo, where wild-type CHIP, but not its U-box
mutant version, induces ErbB2 ubiquitination and down-
regulation. In addition, CHIP enhances the effects of geldana-
mycin treatment, and the U-box mutant of CHIP inhibits
geldanamycin induced ErbB2 ubiquitination.14 In ER-posi-
tive breast cancer MCF7 cells, CHIP overexpression results
in decreased levels of endogenous ER and the attenuation of
ER-mediated gene expression.45 However, it is unclear
whether Met receptor is a target for ubiquitination and pro-
teasomal degradation as a substrate of CHIP. HGF-induced
Met is ubiquitinated and degraded by binding to Cbl19 or
LRIG.18 In contrast, CHIP overexpression reduces Met ex-
pression in the absence of HGF (Figure 1A, B) by enhancing
Met ubiquitination and proteasomal degradation, as Met deg-
radation is blocked by lactacystin or MG132 treatment10 in
the presence of exogenous CHIP (Figure 2A).
In addition, CHIP acts as an upstream regulator of
oncogenic pathways in breast and other cancers, but not lung
cancer.48 We observed CHIP-mediated Met degradation in
the lung cancer cell line H358, which decreased the growth
and invasion of the cells (Figure 5A, B). In lung cancer, Met
overexpression regulates numerous downstream signaling cas-
cades, including STAT3, ERK1/2, and PI3K-Akt.28 Inhibition of
the phosphorylation and signaling output of Akt1/2 or ERK1/2
in the presence of overexpressed CHIP is therefore consistent
with this Met-induced degradation (Supplement 1).
In conclusion, the current study demonstrates that
CHIP is a novel Met-directed E3 Ub ligase. The indepen-
dence of this pathway from the previously characterized Cbl
Ub ligase cascade raises the intriguing possibility that the
dual manipulation of these pathways may lead to more
effective anticancer therapies. Notably, recent reports have
demonstrated that non-small cell lung cancer is a heteroge-
neous group of disorders with a number of genetic and
proteomic alterations, particularly through genetic variation
in Cbl and the functionality of EGFR and Met.46 These
findings highlight the importance of evaluating the correla-
tion between Met receptor overexpression and CHIP muta-
tions in lung cancer. Collectively, these observations indicate
that alterations in the Met degradation pathway may contrib-
ute to enhanced HGF activity in lung cancer. Based on our
results, the chaperone/CHIP pathway, through the regulation
of Met levels, most likely contributes to the development/
progression of this disease, and, as such, provides a potential
target for anticancer therapies.
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